Baxter International is looking to invest in early-stage companies whose offerings complement its existing portfolio of medical products. It will invest up to $200 million in such companies through Baxter Ventures. "As the company's internal capabilities have advanced our late-stage pipeline, we have the capacity to further accelerate the early-stage development of essential therapies," Robert Parkinson, Jr., chairman and CEO of Baxter, said in a statement. Baxter release | Story